MDIPID: Microbiota-drug interaction and disease phenotype interrelation database

References

[1] Ratiner, Karina, Dragos Ciocan, Suhaib K. Abdeen, and Eran Elinav. 2024. “Utilization of the Microbiome in Personalized Medicine.” Nature Reviews Microbiology 22: 291-308. https://doi.org/10.1038/s41579-023-00998-9

[2] Yoon, Sang Eun, Woorim Kang, Seunghyun Choi, Yoon Park, Mauricio Chalita, Hyun KimJe Hee Lee, Dong-Wook Hyun, et al. 2023. “The Influence of Microbial Dysbiosis on Immunochemotherapy-Related Efficacy and Safety in Diffuse Large B-Cell Lymphoma.” Blood 141: 2224-2238. https://doi.org/10.1182/blood.2022018831

[3] Zhao, Qing, Yao Chen, Weihua Huang, Honghao Zhou, and Wei Zhang. 2023. “Drug-Microbiota Interactions: An Emerging Priority for Precision Medicine.” Signal Transduction and Targeted Therapy 8: 386. https://doi.org/10.1038/s41392-023-01619-w

[4] Nguyen, Chi L., Kate A. Markey, Oriana Miltiadous, Anqi Dai, Nicholas Waters, Keimya Sadeghi, Teng Fei, et al. 2023. “High-Resolution Analyses of Associations Between Medications, Microbiome, and Mortality in Cancer Patients.” Cell 186: 2705-2718.e17. https://doi.org/10.1016/j.cell.2023.05.007

[5] Zhang, Fen, Dominik Aschenbrenner, Ji Youn Yoo, and Tao Zuo. 2022. “The Gut Mycobiome in Health, Disease, and Clinical Applications in Association With the Gut Bacterial Microbiome Assembly.” The Lancet Microbe 3: e969-e983. https://doi.org/10.1016/S2666-5247(22)00203-8

[6] Chrysostomou, Despoina, Lauren A. Roberts, Julian R. Marchesi, and James M. Kinross. 2023. “Gut Microbiota Modulation of Efficacy and Toxicity of Cancer Chemotherapy and Immunotherapy.” Gastroenterology 164: 198-213. https://doi.org/10.1053/j.gastro.2022.10.018

[7] Sharma, Anukriti, Mary M. Buschmann, and Jack A. Gilbert. 2019. “Pharmacomicrobiomics: The Holy Grail to Variability in Drug Response?” Clinical Pharmacology & Therapeutics 106: 317-328. https://doi.org/10.1002/cpt.1437

[8] Meng, Jingjing, Yaa F. Abu, Yue Zhang, Yuyin Zhou, Yun Xie, Yan Yan, Junyi Tao, et al. 2023. “Opioid-Induced Microbial Dysbiosis Disrupts Irinotecan (CPT-11) Metabolism and Increases Gastrointestinal Toxicity in a Murine Model.” British Journal of Pharmacology 180: 1362-1378. https://doi.org/10.1111/bph.16020

[9] Wang, Panpan, Yifei Jia, Rongrong Wu, Zhiqiang Chen, and Ru Yan. 2021. “Human Gut Bacterial β-Glucuronidase Inhibition: An Emerging Approach to Manage Medication Therapy.” Biochemical Pharmacology 190: 114566. https://doi.org/10.1016/j.bcp.2021.114566

[10] Sun, Ya-Zhou, De-Hong Zhang, Shu-Bin Cai, Zhong Ming, Jian-Qiang Li, and Xing Chen. 2018. “MDAD: A Special Resource for Microbe-Drug Associations.” Frontiers in Cellular and Infection Microbiology 8: 424. https://doi.org/10.3389/fcimb.2018.00424

[11] Qi, Changlu, Yiting Cai, Kai Qian, Xuefeng Li, Jialiang Ren, Ping Wang, Tongze Fu, et al. 2023. “gutMDisorder v2.0: A Comprehensive Database for Dysbiosis of Gut Microbiota in Phenotypes and Interventions.” Nucleic Acids Research 51: D717-D722. https://doi.org/10.1093/nar/gkac871

[12] Skoufos, Giorgos, Filippos S. Kardaras, Athanasios Alexiou, Ioannis Kavakiotis, Anastasia Lambropoulou, Vasiliki Kotsira, Spyros Tastsoglou, and Artemis G. Hatzigeorgiou. 2021. “Peryton: A Manual Collection of Experimentally Supported Microbe-Disease Associations.” Nucleic Acids Research 49: D1328-D1333. https://doi.org/10.1093/nar/gkaa902

[13] Janssens, Yorick, Joachim Nielandt, Antoon Bronselaer, Nathan Debunne, Frederick Verbeke, Evelien Wynendaele, Filip Van Immerseel, et al. 2018. “Disbiome Database: Linking the Microbiome to Disease.” BMC Microbiology 18: 50. https://doi.org/10.1186/s12866-018-1197-5

[14] Zeng, Xian, Xue Yang, Jiajun Fan, Ying Tan, Lingyi Ju, Wanxiang Shen, Yali Wang, et al. 2021. “MASI: Microbiota-Active Substance Interactions Database.” Nucleic Acids Research 49: D776-D782. https://doi.org/10.1093/nar/gkaa924

[15] Mao, Bingyong, Dongyao Li, Jianxin Zhao, Xiaoming Liu, Zhennan Gu, Yong Q. Chen, Hao Zhang, et al. 2015. “In Vitro Fermentation of Fructooligosaccharides With Human Gut Bacteria.” Food & Function 6: 947-954. https://doi.org/10.1039/c4fo01082e

[16] Zhao, Lin-Yong, Jia-Xin Mei, Gang Yu, Lei Lei, Wei-Han Zhang, Kai Liu, Xiao-Long Chen, et al. 2023. “Role of the Gut Microbiota In Anticancer Therapy: From Molecular Mechanisms to Clinical Applications.” Signal Transduction and Targeted Therapy 8: 201. https://doi.org/10.1038/s41392-023-01406-7

[17] Liu, Lei, Suqi Cao, Weili Lin, Zhigang Gao, Liu Yang, Lixin Zhu, Bin Yang, et al. 2024. “Mimatch: A Microbial Metabolic Background Matching Tool for Mitigating Host Confounding in Metagenomics Research.” Gut Microbes 16: 2434029. https://doi.org/10.1080/19490976.2024.2434029

[18] Zhu, Yanan, Tao Shi, Xia Lu, Zhen Xu, Junxing Qu, Zhiyong Zhang, Guoping Shi, et al. 2021. “Fungal-Induced Glycolysis in Macrophages Promotes Colon Cancer by Enhancing Innate Lymphoid Cell Secretion of IL-22.” The EMBO Journal 40: e105320. https://doi.org/10.15252/embj.2020105320

[19] Limon, Jose J., Jie Tang, Dalin Li, Andrea J. Wolf, Kathrin S. Michelsen, Vince Funari, Matthew Gargus, et al. 2019. “Malassezia Is Associated With Crohn's Disease and Exacerbates Colitis in Mouse Models.” Cell Host & Microbe 25: 377-388. https://doi.org/10.1016/j.chom.2019.01.007

[20] Sendid, Boualem, Marjorie Cornu, Camille Cordier, Julie Bouckaert, Jean Frederic Colombel, and Daniel Poulain. 2024. “From ASCA Breakthrough in Crohn's Disease and Candida Albicans Research to Thirty Years of Investigations About Their Meaning in Human Health.” Autoimmunity Reviews 23: 103486. https://doi.org/10.1016/j.autrev.2023.103486

RIGHTS & PERMISSIONS

2025 The Author(s). iMeta published by John Wiley & Sons Australia, Ltd on behalf of iMeta Science.